通过C-End Degrons将流感a病毒减弱为活疫苗
Ping Wang1,2, Le Li1,2,3,4, Yunfang Chen5
1Shanxi Key Laboratory of Animal Disease Research, Prevention and Control, College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|February 21, 2026
概括
这项研究表明,天然的C端降解子可用于制造新的蛋白解向 (PROTAR) 疫苗. 这些活体减弱疫苗是安全的,有效的,并增强T细胞对流感的免疫力.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 无素-蛋白酶体系统 (UPS) 是开发活体减弱疫苗的目标.
- 化向 (PROTAR) 疫苗技术使用化向降解子 (PTD) 与病毒蛋白融合.
- 之前的PROTAR疫苗开发需要在病毒蛋白的C端放置PTD.
研究的目的:
- 研究自然存在的C端降解子在PROTAR疫苗设计中的一般适用性.
- 创建和评估PROTAR疫苗菌株,使用与流感A M1蛋白融合的C端降解子.
- 为了扩大PROTAR活衰减疫苗技术的多功能性.
主要方法:
- 通过将三个不同的C端降解子纳入流感M1蛋白质,生成PROTAR疫苗菌株.
- 在宿主细胞中评估了蛋白质酶依赖的M1蛋白降解和病毒衰减.
- 在体内评估疫苗的安全性,免疫性和保护功效,包括T细胞反应.
主要成果:
- 所有生成的PROTAR疫苗菌株都表现出蛋白酶体依赖的M1降解和强大的衰减.
- 在工程 TEVp 表达细胞中有效复制的疫苗菌株用于制造.
- 在体内研究显示了安全性,强有力的免疫反应 (幽默,粘膜,T细胞),以及对同源和异源流感感染的保护.
结论:
- 天然C端降解子在PROTAR疫苗设计中广泛适用.
- 使用C端降解子的PROTAR疫苗为活体减弱疫苗开发提供了一个多功能平台.
- 观察到增强的T细胞免疫力,特别是CD8+T细胞依赖的异质保护.
相关概念视频
01:51Vaccinations
Overview
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:27Influenza
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...